The SVRI is driven by the common goal of international initiatives promoted at a political, corporate and academic level to reduce or eliminate suffering and death due to infectious diseases and cancer.
The SVRI will contribute to this goal through exploration, scientific discovery and translation of the discoveries into effective preventive vaccine strategies and therapeutic vaccine interventions for infectious diseases and for cancer.
The SVRI will encompass major facets of basic, clinical and translational research covering predominantly the three major infectious diseases: HIV/AIDS, malaria, tuberculosis, as well as the emerging influenza pandemic threat. The SVRI will also benefit from ongoing efforts in the area of cancer vaccine research.
LATEST NEWS & EVENTS
Discovery of an antibody that neutralizes omicron variants of covid
CHUV and EPFL have discovered a new monoclonal antibody that neutralizes the Omicron variants of SARS-CoV-2. This work, published in Nature Microbiology, opens the way to new prophylactic and therapeutic applications. This new antibody confers complete protection in...
LATEST NEWS & EVENTS
News about IMVACC
A Memorandum of Understanding (MoU) for collaboration on support and development of students from South Africa has been concluded on November 2017 between the following Parties: The South African Medical Research Council (SAMRC) The University of Lausanne (UNIL) The...
ONGOING STUDIES
Immune Setpoint
2018-2020
The Immune Setpoint study is an observational study of 600 healthy volunteers, stratified by age and gender including a subset of individuals who will receive the yellow fever vaccination (YFV).
